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Abstract
Background: The aim of the study was to assess changes of substances of oxidative stress in 
patients treated with cardiac resynchronization therapy (CRT).
Methods: The study comprised 51 patients with median age of 66 years. The presence, severi-
ty, and changes of oxidative stress during CRT were assessed and expressed as malondialdehy-
de (MDA) concentration in plasma or in red blood cells. Antioxidant activity was assessed by 
the activity of catalase (CAT), superoxide dismutase (SOD) and glutathione peroxidase (GPx) 
in red blood cells. The concentration and activities were analyzed directly prior to implanta-
tion, 2–5 days after the procedure and after 6 months. Follow-up (6 months) included clinical, 
echocardiographic and implanted device assessments.
Results: During the follow-up, 14% patients died. The median percentage of biventricular 
pacing was 99.29%. After 6 months 88% of patients improved NYHA, 12% remained as non-
-responders. Left ventricular ejection fraction increased from median 21.5% to 29% (p < 0.05).  
Left ventricular end-diastolic diameter decreased significantly from a median of 69.5 mm to  
63 mm (p < 0.05). After a 6-month study, MDA plasma concentration and the activity levels of 
each antioxidant enzymes (CAT, SOD, GPx) showed a statistically significant reduction (p < 0.05). 
Changes concerning MDA concentrations in red blood cells remained statistically insignificant.
Conclusions: Resynchronization effect oxidative stress by reducing plasma concentration of 
MDA, CAT, SOD and GPX. (Cardiol J 2014; 21, 5: 576–582)
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Introduction
The prevalence of chronic heart failure (HF) in 
the general population amounts to 2–3% and rises 
with age up to 10–20% in elderly populations aged 
70–80 years [1]. If associated with uncorrectable 
causes and irreversible myocardial damage, the 
prognosis of the disease is poor. The presence of 
HF symptoms increases the probability of further 
deterioration of left ventricular (LV) function 
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and imposes a risk of life-threatening ventricular 
arrhythmias. The New York Heart Association 
(NYHA) reports a yearly mortality rate for patients 
with NYHA class III HF to be 20%, with escalation 
up to 50% among class IV HF patients.
Mechanisms of death in HF patients are rela-
ted to their severity. In the population of patients 
with mild or moderate HF left ventricular ejection 
fraction (LVEF) remains a strong predictor of pro-
gnosis of sudden cardiac death — in this population 
sudden cardiac death accounts for the majority of 
total mortality causes [2, 3].
Cardiac resynchronization therapy (CRT) is 
a well-recognized method for the treatment of 
HF, in patients with refractory symptoms, despite 
optimal medical treatment and the presence of 
ventricular asynchrony [4].
Beneficial effects of CRT regarding improve-
ment in clinical status, the quality of life and, most 
importantly, mortality reduction have been proven 
in large clinical trials [5–10].
However, approximately 20–30% of patients 
would not respond to this therapy [11–13].
The current European Society of Cardiology 
guidelines recommend CRT (class I indication) as 
a method for HF treatment in patients presenting 
with sinus rhythm, QRS complex duration ≥ 120 ms, 
LVEF ≤ 35%, and symptoms (NYHA class III–IV) 
despite optimal pharmacological treatment [1, 8]. 
In those with life expectancy exceeding 1 year, 
implantation of a CRT defibrillator (CRT-D) is 
recommended [1, 14].
The impairment of LV function leads to acti-
vation of many neurohumoral mechanisms, cru-
cial particularly for the prognosis and treatment 
options. The pivotal neurohumoral mechanisms 
include activation of the renin–angiotensin–aldo-
sterone system and the catecholaminergic nervous 
system [15]. One of the mechanisms of less estab-
lished pathophysiologic role in CHF in humans is 
oxidative stress in the failing heart [16].
Oxidative stress may lead to cardiac tissue 
damage due to imbalance between increased 
production of reactive oxygen species (ROS) 
and impairment of their neutralization by an-
tioxidant defense systems [17]. ROS are con-
stantly formed in the human body and remo-
ved by antioxidant defenses. An antioxidant is 
a substance which, when present at low concentra-
tions compared to that of an oxidizable substrate, 
significantly delays or prevents oxidation of that 
substrate. Antioxidants can act by scavenging 
biologically important reactive oxygen species (e.g. 
O2
−., H2O2, .OH) by preventing their formation, 
or by repairing the damage that they cause. One 
problem with scavenging-type antioxidants is that 
secondary radicals derived from them can often do 
biologic damage themselves.
Increased production of ROS observed in HF 
derives from several pathogenetic disturbances 
featuring catecholamine auto-oxidation, mitochon-
drial leak, recurrent ischemic episodes, and post 
reperfusion microcirculatory damage, as well as 
from the involvement of biologically active sub-
stances such as angiotensin II, xanthine oxidase, 
nitric oxide synthase and cytokines [16].
ROS contribute to HF etiopathogenesis by 
induction of apoptosis and myocyte necrosis [18], 
as well as by activating the matrix metalloprote-
inases and thus, promoting heart muscle fibrosis 
and harmful remodeling [18, 19].
Heart failure is characterized by increased 
ROS formation on the one hand, accompanied by 
a simultaneous drop in the activity of antioxidant 
enzymes on the other, with the latter resulting from 
growing consumption of antioxidant enzymes for 
neutralization of ROS [17].
Excessive ROS production in the failing heart 
is indirectly indicated by the presence of lipid and 
protein peroxidation products and could be mea-
sured in laboratory tests. One of the most popular 
products in laboratory practice is the thiobarbituric 
acid-reactive substances (TBARS). TBARS as 
important lipid peroxidation products, with their 
main component — malondialdehyde (MDA), are 
indicators of ROS [16, 20].
The aim of the study was to assess changes 
of plasma and erythrocyte MDA concentration 
and the activity of antioxidant enzymes (catalase 
[CAT], superoxide dismutase [SOD] and glutathio-
ne peroxidase [GPx] in red blood cells) in patients 
treated with CRT.
Methods
The study group comprised 51 patients aged 
42–81 years (median age 66, ranging 59–72) ad-
mitted to The Department of Cardiology, Antoni 
Jurasz University Hospital of Collegium Medicum 
in Bydgoszcz, between November 2011 and De-
cember 2012 for CRT device implantation due to 
symptomatic HF, according to the criteria given 
above. For the final analysis 49 patients were 
included. Exclusion of 2 patients resulted from 
switching off the biventricular pacing due to per-
manent diaphragmatic nerve stimulation (1 patient) 
and lack of laboratory tests at 6-month follow-up 
due to blood sample damage (1 patient).
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Demographic and medical characteristics of 
the patients are presented in Table 1. All patients 
remained on optimal pharmacological treatment as 
summarized in Table 2.
The presence, severity, and changes in oxygen 
stress during CRT were assessed by TBARS, and 
expressed as MDA concentration both in plasma 
and in red blood cells (Buege-Aust method [21]). 
The Buege-Aust method was published in 1978 and 
up to date it has been a widespread test for detec-
tion of products of lipid peroxidation. The method 
is based on estimation of aldehydic products of 
lipid peroxidation and their ability to react with 
thiobarbituric acid. This products — “thiobarbituric 
acid reactive substances” (TBARS) — can be easily 
detected by spectrophotometry [22].
Changes in antioxidant activity were assessed 
by measuring the activity of CAT, SOD and GPx in 
red blood cells. The above-mentioned enzymatic 
activities were determined according to Beers-Si-
zer [23], Misra-Fridovich [24] and Paglia-Valentine 
[25] methods, respectively.
The concentration and activity of the above-
-mentioned substances were analyzed directly prior 
to CRT implantation (in the morning on the day of 
the procedure), and then 2–5 days after the proce-
dure (acute phase) and after 6 months. Fasting blood 
samples were acquired from the antecubital vein.
Follow-up was performed after 6 months and 
included clinical (anamnesis, physical examination, 
electrocardiogram), echocardiographic and implan-
ted device assessment. Clinical improvement was 
defined as NYHA class reduction and resolving of 
HF physical symptoms and signs such as edema, 
pulmonary congestion evidenced by pulmonary 
crackles, and S3 gallop.
Statistical analysis
Statistical analysis was performed using the 
Statistica, version 10.0 package (StatSoft, Tulsa, 
Table 1. Basic characteristics of patients with he-
art failure qualified for CRT.
Number of patients 51
Age [years] 66.3
Sex (male/female) 40/11
Etiology of heart failure:
Ischemic (no of patients) 61% (n = 31)
Non-ischemic 39% (n = 20)
NYHA classification:
II 5
III 42
IV 4
Echocardiography:
Ejection fraction [%] 21.5%
LVEDD [mm] 69
Electrocardiography:
Sinus rhythm 46
DDD RV pacing 4
Atrial fibrillation 1
QRS duration [ms] 169.6 ± 20.2 (120–200)
Comorbidities:
Diabetes mellitus 33% (n = 17)
Hypertension 45% (n = 23)
CRT — cardiac resynchronization therapy; NYHA — New York He-
art Association; LVEDD — left ventricular end-diastolic diameter
Table 2. Pharmacological treatment.
Classes of drugs Before CRT  
(n = 51)
2–5 days after CRT  
(n = 49)
6 months after CRT  
(n = 44)
Beta-blockers 48 (94.1%) 49 (96%) 44 (100%)
Angiotensin converting enzyme 39 (76.4%) 41 (80.3%) 33 (75%)
Angiotensin receptor blocker 9 (17.6%) 9 (17.6%) 8 (18.1%)
Diuretics 44 (86.2%) 49 (96%) 41 (93.1%)
Aldosterone antagonists 41 (80.3%) 46 (90.1%) 39 (88.6%)
Digoxin 7 (13.7%) 6 (11.7%) 7 (15.9%)
Nitrates 6 (11.7%) 5 (9.8%) 5 (11.3%)
Acetylsalicylic acid 36 (70.5%) 43 (84.3%) 36 (81.8%)
Statins 38 (74.5%) 44 (86.2%) 40 (90.9%)
Amiodarone 9 (17.6%) 7 (13.7%) 5 (11.3%)
Vitamin K antagonists 1 (1.9%) 6 (11.7%) 5 (11.3%)
Clopidogrel 8 (15.6%) 10 (19.6%) 4 (9.0%)
Low-molecular-weight heparin 11 (21.5%)
CRT — cardiac resynchronization therapy
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OK, USA). The Shapiro-Wilk test demonstrated 
non-normal distribution of the investigated variab-
les. Therefore, continuous variables were reported 
as median values and interquartile ranges. The 
Wilcoxon signed-rank test was used to compare 
continuous variables at different time points. 
Values of p < 0.05 were considered statistically 
significant.
Results
Cardiac resynchronization therapy pacemakers 
(CRT-P) were implanted in 9 (17%) patients, while 
42 (82%) patients received cardiac resynchroniza-
tion therapy defibrillators (CRT-D). During the en-
tire time of the follow-up 7 (14%) patients died — 
5 of them due to cardiovascular events. The median 
percentage of biventricular pacing assessed by the 
data from implanted devices was 99.29% (ranging 
99.15–100%) at the end of 6-month follow-up.
Prior to CRT implantation 40 (95%) patients 
were in NYHA class III and 2 (5%) in NYHA class IV. 
After 6 months 37 (88%) patients improved to NYHA 
class II, while 5 (12%) remained in the same NYHA 
class as before the implantation (non-responders).
Echocardiographic data are summarized in Fi-
gures 1 and 2. LVEF increased from median 21.5% 
(range 18.5–27.75) before the CRT device implan-
tation to 29% (range 24–35) at 6-month follow-up 
(p < 0.05). Respectively, left ventricular end-dia-
stolic diameter (LVEDD) significantly decreased 
from a median of 69.5 mm (range 63–75.75) to 
63 mm (range 55.5–70) (p < 0.05).
MDA concentrations in plasma and the red 
blood cells, as well as the activity levels of CAT, 
SOD and GPx prior to CRT, after 2–5 days and after 
6 months are presented in Table 3 and Figures 3–7.
During the acute period of the study (2–5 days 
after the implantation) a significant increase in MDA 
plasmatic concentration was observed (p < 0.02). 
Similarly, in the acute period, activities of the re-
maining enzymes, except for SOD, showed a trend 
towards increase, but the changes were statistically 
insignificant (p > 0.05).
Table 3. Thiobarbituric acid-reactive substances plasma concentration and catalase, superoxide dis-
mutase, and glutathione peroxidase activity in red blood cells.
Before CRT 2–5 days after CRT 6 months after CRT
pMDA [nmolMDA/mL] 0.41 ± 0.1 0.48 ± 0.12 # Z 0.39 ± 0.05 * Z
rMDA [nmolMDA/gHb] 30.97 ± 9.6 30.84 ± 8.9 28.49 ± 14.2
Catalase [U/gHb] 68.06 ± 7.5 71.49 ± 13.1 63.09 ± 11.9 * Z
Superoxide dismutase [U/gHb] 1013.32 ± 149.7 933.07 ± 114.5 848.13 ± 223.2 * Z
Glutathione peroxidase [U/gHb] 9.16 ± 5.5 9.26 ± 4.9 5.87 ± 3.3 * Z
*Statistical significance (p < 0.05) between measurements prior to and 6 months after CRT; #Statistical significance (p < 0.05) between me-
asurements prior to and 2–5 days after CRT; Z Statistical significance (p < 0.05) between measurements 2–5 days after and 6 months after 
CRT; CRT — cardiac resynchronization therapy; pMDA — plasma concentration of malondialdehyde; rMDA — red blood cells concentration 
of malondialdehyde
Figure 1. Changes in left ventricular ejection fraction 
(LVEF) before cardiac resynchronization therapy (CRT) 
implantation and after 6 months of pacing.
Figure 2. Changes in left ventricular end diastolic dia-
meter before cardiac resynchronization therapy (CRT) 
implantation and after 6 months of pacing.
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After 6 months of CRT pacing MDA plasma 
concentration and the activity levels of each antio-
xidant enzyme measured in red blood cells (CAT, 
SOD, GPx) showed a statistically significant re-
duction (p < 0.05). Analogous changes concerning 
MDA concentrations in red blood cells remained 
statistically insignificant.
Discussion
Heart failure per se, regardless of its etiology, is 
associated with elevation of oxidative stress markers 
(i.e. increase in TBARS concentration, indicative of 
ROS presence). There is often a directly proportional 
correlation between the magnitude of this elevation 
and the degree of HF progression [16, 20, 26–31].
Figure 3. Malondialdehyde (MDA) plasma concentra-
tion before and after cardiac resynchronization therapy 
(CRT) implantation.
Figure 4. Malondialdehyde (MDA) red blood cells con-
centration before and after cardiac resynchronization 
therapy (CRT) implantation.
Figure 5. Catalase (CAT) activity in red blood cells be-
fore and after cardiac resynchronization therapy (CRT) 
implantation.
Figure 6. Superoxide dismutase (SOD) activity in red 
blood cells before and after cardiac resynchronization 
therapy (CRT) implantation.
Figure 7. Glutathione peroxidase (GPx) activity in red 
blood cells before and after cardiac resynchronization 
therapy (CRT) implantation.
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Polidori et al. [28] reported higher plasma 
concentrations of MDA in NYHA class III patients 
as compared with NYHA class II patients, as well 
as an inverse correlation between MDA concentra-
tion and LVEF. Similar findings were presented by 
Belch et al. [26] and Keith et al. [30]. Additionally, 
a decrease in MDA concentration is a common 
finding coexisting with clinical improvement in 
this group of patients.
In a study by Castro et al. [32], a decline in 
MDA plasma concentration in patients with clinical 
improvement occurred after medical therapy, in 
contrast to MDA concentration in non-responders.
In our study group, improvement in the clinical 
status of patients and reverse remodeling after 
6 months of CRT pacing were associated with at-
tenuation of oxidative stress as assessed by MDA 
plasma concentration.
As described in literature, CRT results in re-
verse remodeling of the LV and an increase in LVEF 
by 6–11% during the first 3–6 months [33–37]. 
According to our observations, resynchronization 
therapy leads to reduction of oxidative stress in the 
failing heart as expressed by decreasing concen-
trations of lipid peroxidation products.
Oxidative stress in the failing heart results 
from imbalance between excess of free radicals 
production and coexisting impairment of antioxi-
dant defenses in myocardium. Antioxidant activity 
may be assessed by measuring activities of specific 
enzymes (the most important of which are intra-
cellular enzymes such as CAT, SOD, or GPx) or 
non-enzymatic substances such as vitamins C or E. 
Since literature data regarding changes of antio-
xidant substances in chronic HF mainly concern 
antioxidant enzymes, in contrast to non-enzymatic 
mechanisms [33], we decided to research into the 
former.
Depressed activity of the antioxidant enzy-
mes usually occurs in response to elevation of 
ROS concentrations in HF [21]. The majority of 
authors explain it by enhanced participation of the 
antioxidant system in neutralization of ROS. Rado-
vanovic et al. [38] stated that antioxidant enzymes 
activity can also change in response of progression 
of HF. Moreover, there can be different tendencies 
regarding different enzymes. GPx significantly 
decreases along with progression of NYHA class 
and LVEDD, as well as with lowering of LVEF. 
SOD, in turn, demonstrates opposite direction of 
changes, with a significant increase in its activity 
along with progression of HF [38].
Interestingly, in our study, the activity of antio-
xidant enzymes responsible for ROS neutralization 
after 6 months of CRT therapy decreased when 
compared with baseline values. It seems that this 
decrease may be associated with the reduction of 
oxygen stress during the therapy. However, our 
data contradict observations of many researchers 
who reported depressed antioxidant activity as 
a marker of elevation of reactive oxygen specific for 
HF and increasing antioxidant enzymes activity in 
response to treatment [26]. It is interesting to note 
that our results concern the activity of enzymes 
measured inside the cells (intracellular antioxidant 
activity), but not in plasma. 
Limitations of the study
It should also be underlined that the limited 
duration of follow-up in our study does not allow to 
determine whether further clinical improvement of 
the patients will be correlated with further chan-
ges in MDA concentrations or an increase in the 
activity of the antioxidant enzymes.
Conclusions
Plasma activities of antioxidant enzymes are 
probably related to a systemic reaction to oxidative 
stress, but the intra-cellular decrease in the above-
-mentioned enzymes may suggest that there is no 
need for antioxidant activity enhancement due to 
reduction of oxygen stress at cellular level.
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